Absorbable lateral nasal implant for nasal valve collapse
Defines coverage stance for insertion of absorbable lateral nasal implants to treat symptomatic nasal valve collapse for BlueCHiP for Medicare and Commercial products; describes evidence background and billing guidance.
No material clinical or coverage changes in this update.
Coverage Summary & Determination
This policy addresses the use of absorbable lateral nasal implants as a treatment for symptomatic nasal valve collapse. The coverage stance is not covered / cosmetic (policy: not_covered_cosmetic). Evidence is limited and primarily consists of nonrandomized, industry‑sponsored cohorts with heterogeneous populations, incomplete outcomes and follow‑up shorter than device absorption/remodeling periods, so benefits on health outcomes are uncertain.